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Objectives: Fatigue is an important symptom for multiple sclerosis (MS) patients. 
Qualitative research supported initial content validity of the FSIQ-RMS™,1 the 
first patient-reported outcome (PRO) measure of fatigue in relapsing (R)MS 
developed according to the 2009 FDA PRO guidance. To confirm appropriate-
ness, validity, and reliability of the FSIQ-RMS, further psychometric analyses 
were required. MethOds: The FSIQ-RMS™ with 9 Symptom items (daily recall 
period, 1 subdomain) and 14 Impact items (weekly recall period, 3 subdomains) 
was administered over 3 months (three 7-day intervals) in a multicenter, non-
interventional, US-based, IRB-approved study to adult patients with different RMS 
subtypes (relapsing remitting, secondary progressive, progressive relapsing) and 
a subset of matched healthy controls (week 1 only). Data analyses included: item 
response and dimensionality; content and construct validity; internal consistency 
and test-retest reliability; as well as attribution of fatigue to RMS. Evaluations 
were supported by those from a cross-sectional, multicenter study, in which RMS 
patients completed the FSIQ-RMS™ Symptoms domain. Results: The psycho-
metric validation study included 164 RMS patients (mean age 45 [range 19–65] 
years; 76% female) and 74 controls (40 [18–65] years; 73% female). Two redundant 
Symptom items were deleted, leaving 7; Impact items were unchanged. A 0–100 
scoring algorithm was developed for the FSIQ-RMS™ (sub)domains. Internal con-
sistency (Cronbach’s alpha 0.87–0.97) and test-retest reliability (intraclass cor-
relation coefficient [ICC] 0.92–0.95) of all (sub)domains exceeded pre-specified 
thresholds (alpha> 0.70; ICC≥ 0.70). The Symptoms domain discriminated along the 
symptom-severity continuum of RMS patients and between patients and healthy 
controls. Patients were able to attribute fatigue-related symptoms to RMS (14-point 
difference vs. controls; P< 0.0001). Findings were supported by those from the 
cross-sectional study (N= 154). cOnclusiOns: Content and measurement validity 
of the revised final FSIQ-RMS™ were confirmed. Responsiveness of the PRO will 
be evaluated in a Phase III trial. 1Value Health 2014;17(3):A195-6.
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Objectives: To assess the feasibility of the SF-36v2 Mental Health (MH) domain 
and Mental Component Summary (MCS) scores in the classification of risk for 
major depressive disorder (MDD), and determine the cutoff scores in a US sam-
ple and chronic pain subpopulations. MethOds: Data were analyzed from the 
2013 US National Health and Wellness Survey (adults ≥ 18 years old; N= 75,000). 
Respondents were also classified into subpopulations based on self-report: chronic 
pain (n= 6,679) and chronic pain receiving medication for depression (i.e. with 
depression) (n= 5,814). The primary definition for classifying respondents at risk 
of MDD was a score > 10 on the Patient Health Questionnaire (PHQ-9). Logistic 
regression modeling was used to predict at risk for MDD, or not, and receiver 
operating characteristic curves were produced. Results: The total sample had 
MH scores of 48.8 and MCS scores of 48.9, similar to the normative mean for the 
US adult population. The percent of respondents with a PHQ-9 > 10 were 15.0%, 
29.1% and 25.9% for the total sample, chronic pain alone, and chronic pain with 
depression, respectively. Cutoff scores (PHQ-9> 10) in the total sample for the MH 
domain and MCS were 43.0 and 46.0, respectively. Specificities of recommended 
cutoff scores for the MH domain and MCS were 77.8% and 76.1%; sensitivities 
were 84.9% and 88.1%. Among the subpopulation with chronic pain alone, cutoff 
scores for the MH domain and MCS were 40.4 and 43.1, respectively. Corresponding 
specificities for the MH domain and MCS were 77.9% and 73.9%; sensitivities were 
78.3% and 83.4%. Trends were similar among the chronic pain with depression 
subpopulation. cOnclusiOns: The SF36v2 was found to have sufficient specific-
ity and sensitivity to categorize participants at risk for MDD. It is feasible to use 
the SF-36v2, a widely used measure to assess health status, to better characterize 
the mental health of populations.
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Objectives: Little is known about estimating utilities for comorbid (or ‘joint’) 
health states. Several joint health state prediction models have been suggested (for 
example, additive, multiplicative, best-of-pair, worst-of-pair, etc.) but no general 
consensus has been reached. Without preconceptions about the preferred func-
tional form, this study explores the relationship between health-related quality of 
life (HRQoL) and increasing numbers of diagnoses. MethOds: We analyzed a large 
dataset containing respondents’ ICD-9 diagnoses and preference-based HRQoL 
(EQ-5D and SF-6D). Data were stratified by the number of diagnoses and mean 
HRQoL values were estimated. Several adjustments, accounting for the respond-
ents’ age, sex and the severity of the diagnoses were carried out. Our analysis fitted 
additive and multiplicative models to the data, and assessed model fit using mul-
tiple standard model selection methods. Results: A total of 39817 respondents 
were included in the analyses. Average HRQoL values were represented well by 
both linear and multiplicative models. Although results across all analyses were 
similar, adjusting for severity of diagnoses, age and sex strengthened the linear 
model’s performance measures relative to the multiplicative model. Adjusted 
values were above 0.99 for all analyses (i.e. all adjusted analyses, for both HRQoL 
instruments), indicating a robust result. cOnclusiOns: Additive and multiplica-
tive models perform equally well within our analyses. Presupposing that a lin-
ear model is simpler than an additive one, we conclude that the additive model 
should be preferred unless compelling evidence is produced to show that the 
models diverge.
with COPD, a total of 33.3% patients showed moderate to severe depressive symp-
toms and nearly 50% of cases had a marked impairment in HRQol. Educational and 
occupational status, body mass index, FEV1, respiratory symptoms, physical impair-
ment and dyspnoea were associated with the diagnosis of depression in patients 
with COPD, whereas, body- mass-index, forced expiratory volume in 1 second (FEV1 
), dyspnea grade, and depression were associated with poor HRQL in patients with 
COPD. cOnclusiOns: More than one third of patients with COPD had either depres-
sion or poor HQol in India. The study suggest need for regular screening for depres-
sion and HRQol in patients with COPD especially among obsese and patients with 
comprosised or severe respiratory functions.
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Objectives: As a disease characterized by pain, Patient-Reported Outcomes (PROs) 
are important for determining disease severity and evaluating the efficacy of endo-
metriosis treatments. In the absence of existing PROs that comply with the FDA PRO 
Guidance, two new PROs have been developed: The Endometriosis Symptom Diary 
(ESD) and Endometriosis Impact Scale (EIS). The content validity of these instruments 
has been demonstrated by extensive qualitative and quantitative research with 
women with endometriosis. The first investigations of the reliability and validity of 
scores derived from the ESD and EIS are presented herein. MethOds: Women with 
surgically-confirmed endometriosis (n= 268) in the US and Germany participated in 
a 12-week non-interventional study. A range of PRO measures were completed by 
participants throughout the study using an electronic handheld device, including: 
ESD, EIS, Biberoglu & Behrman Scale, Endometriosis Health Profile-30, Patient Global 
Impression of Severity and Change measures and single-item pain numerical-rating 
and visual analogue scales. Pre-specified analyses were conducted to evaluate the 
test-retest reliability, convergent validity, known-groups validity and responsiveness 
of scores derived from the ESD and EIS. Results: Intraclass correlation coefficients 
among participants classified as ‘stable’ support the test-retest reliability of ESD/EIS 
scores. Correlations between scores for the ESD/EIS and concurrent measures were 
consistent with a priori hypotheses, demonstrating convergent validity. Furthermore, 
Analysis of Covariance models revealed statistically significant (p< 0.05) differences 
in ESD/EIS scores among participants of varying levels of symptom severity (as deter-
mined by scores on concurrent measures). Finally, observed ESD/EIS score changes 
in participants whose clinical status had improved (according to scores on concur-
rent measures) were significantly greater than those who had not improved/changed, 
providing evidence of responsiveness. cOnclusiOns: Findings support the reliability 
and validity of scores derived from the ESD and EIS. Future research will seek to explore 
definitions of meaningful change in ESD/EIS scores using data from clinical studies.
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Objectives: Selection of response scales for patient-reported outcome (PRO) 
measures is often driven by therapeutic area convention or preferences of measure 
developers. To help guide response scale selection, an objective of this project was 
to identify empirical evidence supporting the responsiveness of common response 
scale types. MethOds: A comprehensive literature review was conducted for stud-
ies published from January 2004 through October 2014 that provided direct compari-
sons of responsiveness of different response scale types. Additional searches were 
conducted for abstracts and presentations on this topic from relevant scientific con-
ferences. Results: The most common types of response scales evaluated were the 
100mm visual analog scale (VAS), the 11-point numeric rating scale (NRS), and the 
verbal rating scale (VRS) (with varying number of levels). Three studies directly com-
pared responsiveness of all three types. Of these, one found no difference in respon-
siveness of the three types, one found superior responsiveness for the NRS compared 
to the VAS, and one found the VAS to be most responsive for one domain while the 
NRS was most responsive for another. Three studies compared VAS to VRS, with one 
finding no difference and one study each finding greater responsiveness for the VAS 
and a 7-point VRS, respectively. Four studies compared NRS vs. VRS, with three dem-
onstrating no difference and one demonstrating superior responsiveness for the NRS 
compared to a 6-point VRS. cOnclusiOns: There are a number of considerations in 
response scale selection, including target population, study design, concept of interest, 
recall period, data collection mode, and scale responsiveness. Several reviewed studies 
demonstrated equivalent responsiveness for the most common response scale types; 
however, evidence suggests the 11-point NRS may be slightly more responsive than the 
other response scales in some settings. Limitations of this review include its 10-year 
timeframe and the paucity of empirical studies comparing common response scales.
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